AGM/EGMMay 29, 2026, 04:18 PM
Enveric Biosciences Stockholders Approve Reverse Split, Reject Stock Increase
AI Summary
Enveric Biosciences, Inc. held its 2026 Annual Meeting of Stockholders, where a proposal to effect a reverse stock split (1-for-5 to 1-for-15) was approved. However, a proposal to increase the authorized common stock from 100 million to 5 billion shares was rejected by stockholders. Additionally, six directors were elected, executive compensation was approved on an advisory basis, and CBIZ CPAs P.C. was ratified as the independent auditor. Separately, the Board of Directors approved new Restricted Stock Unit and Restricted Stock Award agreements under the Company's 2020 Long-Term Incentive Plan.
Key Highlights
- Stockholders approved the Reverse Stock Split Proposal with 793,344 votes For.
- Stockholders rejected the Authorized Stock Increase Proposal with 555,147 votes Against.
- Six directors were elected to serve until the 2027 annual meeting.
- The advisory Say-on-Pay Proposal was approved with 569,552 votes For.
- The appointment of CBIZ CPAs P.C. as the independent auditor for 2026 was ratified.
- New Restricted Stock Unit (RSU) and Restricted Stock Award (RSA) agreements were approved under the 2020 Long-Term Incentive Plan.
- The RSU Agreement provides for time-based vesting over four years, with 25% vesting on the first anniversary.
- The RSA Agreement provides for time-based vesting on a specified date, subject to continued service.
Price Impact
More from ENVB